Med Spa Peptide Therapy Program: What You Can Offer in 2026

A med spa peptide therapy program can combine an existing spa brand with clinician-led telehealth, but the spa cannot treat “peptides” as one legally defined product category. The program must classify each product, use authorized clinicians for evaluation and prescribing, follow federal compounding rules, meet the law where the patient is located, and advertise only claims supported by evidence.

Can a med spa offer peptide therapy?

Yes, a med spa can add peptide-related medical services when the clinical, pharmacy, ownership, telehealth, and advertising arrangements comply with federal and state requirements. The spa’s existing team may handle administrative and nonclinical services, but diagnosis, eligibility, product selection, prescribing, follow-up, and discontinuation belong to the licensed medical practice and its clinicians.

The first business decision is not which peptide to put on a menu. It is which clinical service the practice can lawfully operate and support. The answer depends on:

• The specific active ingredient and its FDA status;
• Whether the product is FDA-approved or compounded;
• The state where the patient is physically located;
• Whether the clinician evaluates the patient in person or through telehealth;
• Which entity owns the medical practice, records, website, and prescribing relationship;
• Whether the med spa dispenses, administers, or only coordinates prescriptions.

MDLaunchr operates white-label telehealth infrastructure for branded programs, while independently licensed clinicians retain responsibility for medical decisions. That can help a spa organize the business layer, but a platform does not replace state licensure, medical-practice ownership analysis, pharmacy review, or clinical governance.

What can a med spa peptide therapy program include?

A defensible program usually begins with a narrow, product-specific formulary rather than a broad peptide catalog. FDA-approved medications that may be considered in an appropriate clinician-led program include semaglutide, tirzepatide, and liraglutide, subject to their approved labeling, prescribing requirements, and the clinician’s individualized judgment. An FDA-approved medication and a compounded formulation are not the same regulatory category.

Compounded products do not receive FDA premarket approval. FDA states that compounded drugs are not reviewed in the same way as FDA-approved drugs for safety, effectiveness, or quality before marketing. Therefore, a spa should not describe a compounded formulation as FDA-approved or imply that it has the same regulatory status as an approved product.

The product file for every proposed therapy should identify:

1. 1The active ingredient and formulation.
2. 2Whether an FDA-approved product exists.
3. 3The approved indication and route, if an approved product is being discussed.
4. 4The pharmacy or outsourcing facility involved.
5. 5Whether the proposed compounding model is 503A or 503B.
6. 6Current federal and state pharmacy requirements.
7. 7The evidence supporting each proposed advertising claim.
8. 8Recall, complaint, adverse-event, labeling, and lot-tracking procedures.

This product-by-product approach matters because FDA has identified safety concerns for some bulk substances considered for compounding. It also states that biological products are not eligible for the ordinary 503A or 503B compounding exemptions outside the applicable biologics framework. A demand-driven internet catalog is not a substitute for ingredient-level review.

At-a-glance: who owns each part of the program?

State law decides how these roles can be arranged. The table is an operating framework, not a national ownership rule.

How do 503A and 503B rules affect med spa peptides?

503A and 503B are different federal compounding pathways, and a med spa should not treat them as interchangeable pharmacy labels.

What does 503A mean for a med spa?

Under FDA’s description of section 503A, compounding is generally tied to an individual patient prescription or patient-specific order and performed by a licensed pharmacist in a state-licensed pharmacy, federal facility, or licensed physician subject to statutory conditions. A med spa should not assume that a prepaid service or generalized product inventory satisfies the patient-specific requirement.

FDA also states that a 503A compounder generally may not regularly or inordinate amounts compound a drug that is essentially a copy of a commercially available drug. FDA’s April 2026 communication highlighted this issue as GLP-1 supply conditions changed. Before relying on a 503A model, the business should understand how the pharmacy receives patient-specific orders, evaluates the prescription, labels the product, and handles dispensing.

What does 503B mean for a med spa?

A 503B outsourcing facility operates under separate statutory requirements and FDA oversight. FDA states that, in most cases, an outsourcing facility cannot use a bulk drug substance unless it appears on the FDA 503B bulk list or the compounded drug is on the FDA drug-shortage list at the relevant time.

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug list and invited comments through June 29, 2026. The proposal was not itself a final rule. A med spa should verify the final status before relying on a 503B supply model or signing a pharmacy agreement.

For either pathway, request documentation rather than relying on a sales description. Review the facility’s registration and state licenses, product-specific authority, dispensing arrangement, labeling, lot procedures, recalls, complaints, and adverse-event process.

For a deeper look at the federal framework, see the FDA peptide compounding rules for telehealth clinics. The same principles apply when a med spa extends its existing brand into telehealth.

What clinician and telehealth rules apply?

The clinician must be authorized to practice where the patient is located and must meet applicable standards for evaluation, documentation, prescribing, informed consent, privacy, and follow-up. A questionnaire-only model is not a safe substitute for individualized medical judgment.

A med spa peptides telehealth workflow should include:

• Patient identity and physical-location verification;
• Licensure verification for the patient’s state;
• Medical history and medication reconciliation;
• A documented evaluation appropriate to the service;
• Screening for relevant contraindications and clinical concerns;
• Individualized medical rationale;
• Informed consent;
• A follow-up and adverse-event pathway;
• Records retained by the medical practice;
• Clear boundaries preventing sales or esthetics staff from making clinical recommendations.

Controlled substances require additional attention. DEA and HHS extended temporary telemedicine flexibilities through December 31, 2026. Under the extension, DEA-registered practitioners may prescribe Schedule II–V controlled substances by audio-video telemedicine without a prior in-person evaluation when applicable federal and state conditions are met. The extension does not remove the requirement for a legitimate medical purpose, an authorized prescriber, and compliance with state and federal law.

A med spa owner should therefore avoid describing the whole program as a retail service. The commercial workflow can be streamlined, but the clinical encounter must remain individualized and controlled by the medical practice.

Does state law change how a med spa can add peptides?

Yes. Rules vary by state, and the med spa’s location is not the only relevant jurisdiction. The patient’s physical location generally determines where the clinician is practicing for telehealth purposes. Ownership, supervision, prescriptive authority, entity structure, and records control can also differ.

California: clinical control and corporate-practice restrictions

In California, the Medical Board states that corporations and other artificial entities do not have professional rights, privileges, or powers under Business and Professions Code section 2400. The Board warns that nonphysicians may not control diagnosis, treatment options, referrals, medical records, physician workload, or staffing decisions based on clinical competency.

California also requires the physician treating a patient located in California through telehealth to be California licensed, with the same standard-of-care and informed-consent responsibilities that apply to in-person care. A nonphysician-owned spa should not assume that appointing a medical director permits the spa entity to own or control the medical practice. Professional-entity, MSO, compensation, advertising, and records arrangements need state-specific analysis.

Texas: telehealth does not lower the standard of care

In Texas, an act affecting the diagnosis or treatment of a patient in Texas can constitute the practice of medicine in Texas, even when the clinician is outside the state. Texas materials state that online treatment and prescribing are held to the same standards as in-person care and that a questionnaire-only evaluation is not an acceptable standard of care.

Texas also requires physician registration and a prescriptive-authority agreement when a physician delegates prescriptive authority to an APRN or PA. A Texas med spa can use telehealth, but “online-only” does not mean protocol-only. The program needs an adequate evaluation, documentation, and compliant delegation structure.

Florida: telehealth evaluation flexibility still has limits

Florida Department of Health guidance states that telehealth providers may evaluate patients through telehealth and are not automatically required to research the patient’s history or perform a physical examination before using telehealth when the evaluation is sufficient to diagnose and treat. The provider must still practice within scope and meet the prevailing professional standard applicable to in-person care.

Florida’s framework also includes requirements for patient evaluations, records, and controlled-substance prescribing. That flexibility does not authorize unlicensed spa personnel to diagnose, prescribe, or make clinical recommendations.

New York: telehealth and corporate practice must be analyzed together

New York Health Department guidance states that unauthorized corporate-practice restrictions generally prevent an unlicensed corporation or entity from providing or arranging professional services unless authorized by statute or regulation. New York prescribing regulations permit certain telemedicine prescribing when consistent with New York law and DEA rules.

For a New York med spa, telehealth availability does not eliminate questions about professional-entity ownership, physician contracting, MSO services, compensation, advertising, and control of the patient relationship. A national program needs a state matrix rather than one universal agreement.

How should a med spa advertise peptide therapy?

Advertising must be truthful, not misleading, and supported by competent and reliable scientific evidence before publication. FTC guidance applies to websites, landing pages, paid search, social media, email, testimonials, influencer content, and patient reviews used in marketing.

Review the complete consumer impression, not just the disclaimer. Risky patterns include:

• Calling a compounded product “FDA-approved”;
• Using “clinically proven” without evidence for the exact product and claim;
• Promising weight loss, hormone balancing, anti-aging, or disease reversal;
• Saying a therapy has no side effects or is safe for everyone;
• Using before-and-after images or testimonials that imply typical results without appropriate qualification;
• Advertising a product as available before a clinician determines that it is medically appropriate;
• Using names, imagery, or headlines that imply stronger evidence than the page can support.

The med spa weight-loss advertising rules for FTC and FDA compliance are especially relevant if the program discusses medications whose approved labeling includes weight-related indications. Keep the service description, clinical claims, testimonials, and product-status language aligned.

What should an owner review before adding peptides to a med spa?

Use this launch sequence before accepting patients:

1. 1Define the service. Decide whether the spa is coordinating clinician-led care, offering an FDA-approved medication program, or considering a compounded pathway.
2. 2Classify every product. Create a product file for active ingredient, formulation, FDA status, labeling, compounding authority, and supporting evidence.
3. 3Map state requirements. Identify clinician licenses, telehealth rules, supervision, prescriptive authority, corporate-practice limits, pharmacy rules, advertising restrictions, and record requirements.
4. 4Separate clinical control. Put diagnosis, eligibility, product selection, prescribing, follow-up, and discontinuation under the medical practice and licensed clinicians.
5. 5Vet the pharmacy. Verify registration, state licenses, dispensing model, labeling, lot controls, recalls, complaints, and adverse-event procedures.
6. 6Build the telehealth workflow. Include identity, location, history, evaluation, consent, documentation, follow-up, and escalation procedures.
7. 7Review the marketing. Remove unsupported outcome claims, inaccurate FDA language, misleading testimonials, and product promises made before clinical evaluation.
8. 8Test the operating model. Confirm who owns the records, patient relationship, website, protocols, billing, clinical revenue, and patient communications in each launch state.
9. 9Document ongoing review. Assign responsibility for FDA status changes, state-law updates, pharmacy changes, complaints, recalls, and advertising revisions.

MDLaunchr and WhiteLabelClinic.com are one infrastructure option for a branded telehealth program. The platform can support the business and workflow layer, but it does not independently determine which products are lawful in a state, replace a medical director or prescribing clinician, or guarantee pharmacy availability or regulatory approval.

For owners comparing several service lines, the multi-program telehealth platform guide explains why separate clinical, pharmacy, billing, and advertising controls matter across programs.

Once those decisions are documented, see the white-label peptide therapy program as one infrastructure option for extending an existing med spa brand into clinician-led telehealth.

Related reading: the full guide this article belongs to.